Last reviewed · How we verify
Typbar-TCV™
At a glance
| Generic name | Typbar-TCV™ |
|---|---|
| Sponsor | EuBiologics Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Typbar-TCV™ CI brief — competitive landscape report
- Typbar-TCV™ updates RSS · CI watch RSS
- EuBiologics Co.,Ltd portfolio CI